Organon (OGN) Appoints Ramona A. Sequeira to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
April 15, 2025 5:00 PM EDTJERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) a global healthcare company with a focus on womens health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organons Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Boards Talent Committee. In connection with Ms. Sequeiras appointment, the size of Organons Board will be expanded to 12 directors.
Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company... More
